Publisher's Synopsis
Examine the strong evidence of this unrealized pain management tool
Cholecystokinin (CCK), the regulatory peptide hormone found primarily in the gastrointestinal tract that works as a neurotransmitter throughout the nervous system, has been researched for years. CCK antagonists in conjunction with opioids are beginning to be seen as having possible major therapeutic benefits in pain management. Cholecystokinin and Its Antagonists in Pain Management is an extensive examination that gathers the mounting compelling evidence into one comprehensive source. Here researchers, neuroscientists, physicians, and pharmacy professionals are given the research and findings they need to explore the possible applications of CCK antagonists for a variety of illnesses.
Cholecystokinin and Its Antagonists in Pain Management extensively describes opioids in pain management, CCK and the body's uses for the chemical, CCK receptor antagonists, and the evidence that points to its being a possible breakthrough application in pain management. Various animal studies are offered that present a convincing view of what may be the future of chronic pain management, with less side effects and a reduction in analgesic tolerance than when opioids are used alone. Potential uses of CCK antagonists are clearly discussed. The book is comprehensively referenced and provides several tables and graphs to fully illustrate the research findings.
Topics in Cholecystokinin and Its Antagonists in Pain Management include:
- in vivo localization of CCK
- CCK as a gut and nervous system peptide
- factors that increase CCK
- anti-opioid effects
- CCK receptor antagonists
- pro-analgesic effect of CCK antagonists
- CCK antagonists reducing analgesic tolerance to opioids
- safety of combining opioids and CCK antagonists
- human clinical application of CCK antagonists
Cholecystokinin and Its Antagonists in Pain Management is a crucial source of the latest information and research results on CCK that is certain to be important for neuroscientists, clinicians, and pharmaceutical industry professionals.
